Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells.
Journal
Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
received:
29
12
2022
accepted:
29
09
2023
medline:
28
11
2023
pubmed:
28
11
2023
entrez:
27
11
2023
Statut:
aheadofprint
Résumé
Few cancers can be targeted efficiently by engineered T cell strategies. Here, we show that γδ T cell antigen receptor (γδ TCR)-mediated cancer metabolome targeting can be combined with targeting of cancer-associated stress antigens (such as NKG2D ligands or CD277) through the addition of chimeric co-receptors. This strategy overcomes suboptimal γ9δ2 TCR engagement of αβ T cells engineered to express a defined γδ TCR (TEGs) and improves serial killing, proliferation and persistence of TEGs. In vivo, the NKG2D-CD28
Identifiants
pubmed: 38012415
doi: 10.1038/s41590-023-01665-0
pii: 10.1038/s41590-023-01665-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Sebestyen, Z. et al. RhoB mediates phosphoantigen recognition by V
pubmed: 27210746
pmcid: 5035041
doi: 10.1016/j.celrep.2016.04.081
Rigau, M. et al. Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells. Science 367, eaay5516 (2020).
pubmed: 31919129
doi: 10.1126/science.aay5516
Karunakaran, M. M. et al. Butyrophilin-2A1 directly binds germline-encoded regions of the V
pubmed: 32155411
pmcid: 7083227
doi: 10.1016/j.immuni.2020.02.014
Mamedov, M. R. et al. CRISPR screens decode cancer cell pathways that trigger γδ T cell detection. Nature 621, 188–195 (2023).
pubmed: 37648854
doi: 10.1038/s41586-023-06482-x
Harly, C. et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood 120, 2269–2279 (2012).
pubmed: 22767497
pmcid: 3679641
doi: 10.1182/blood-2012-05-430470
Hsiao, C. C. et al. Ligand-induced interactions between butyrophilin 2A1 and 3A1 internal domains in the HMBPP receptor complex. Cell Chem. Biol. 29, 985–995 (2022).
pubmed: 35081362
doi: 10.1016/j.chembiol.2022.01.004
Yuan, L. et al. Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate V
pubmed: 37674084
pmcid: 10533412
doi: 10.1038/s41586-023-06525-3
Vyborova, A. et al. γ9δ2T cell diversity and the receptor interface with tumor cells. J. Clin. Invest. 130, 4637–4651 (2020).
pubmed: 32484803
pmcid: 7456241
doi: 10.1172/JCI132489
Gründer, C. et al. γ9 and δ2CDR3 domains regulate functional avidity of T cells harboring γ9δ2TCRs. Blood 120, 5153–5162 (2012).
pubmed: 23018643
doi: 10.1182/blood-2012-05-432427
Straetemans, T. et al. Untouched GMP-ready purified engineered immune cells to treat cancer. Clin. Cancer Res. 21, 3957–3968 (2015).
pubmed: 25991821
doi: 10.1158/1078-0432.CCR-14-2860
de Witte, M. et al. First in human clinical responses and persistence data on TEG001: a next generation of engineered αβ T cells targeting AML and MM with a high affinity γ9δ2TCR. Blood 140, 12737–12739 (2022).
doi: 10.1182/blood-2022-158191
Dekkers, J. F. et al. Uncovering the mode of action of engineered T cells in patient cancer organoids. Nat. Biotechnol. 41, 60–69 (2022).
pubmed: 35879361
pmcid: 9849137
doi: 10.1038/s41587-022-01397-w
Fuertes, M. B., Domaica, C. I. & Zwirner, N. W. Leveraging NKG2D ligands in immuno-oncology. Front. Immunol. 12, 713158 (2021).
pubmed: 34394116
pmcid: 8358801
doi: 10.3389/fimmu.2021.713158
Marcu-Malina, V. et al. Redirecting αβ T cells against cancer cells by transfer of a broadly tumor-reactive γδ T-cell receptor. Blood 118, 50–59 (2011).
pubmed: 21566093
doi: 10.1182/blood-2010-12-325993
Benyamine, A. et al. BTN3A is a prognosis marker and a promising target for V
pubmed: 29296524
pmcid: 5739572
doi: 10.1080/2162402X.2017.1372080
Palakodeti, A. et al. The molecular basis for modulation of human V
pubmed: 22846996
pmcid: 3463320
doi: 10.1074/jbc.M112.384354
De Gassart, A. et al. Development of ICT01, a first-in-class, anti-BTN3A antibody for activating V
pubmed: 34669444
doi: 10.1126/scitranslmed.abj0835
Mansilla-Soto, J. et al. HLA-independent T cell receptors for targeting tumors with low antigen density. Nat. Med. 28, 345–352 (2022).
pubmed: 35027758
pmcid: 9469647
doi: 10.1038/s41591-021-01621-1
Oda, S. K. et al. A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy. J. Exp. Med. 217, e20191166 (2020).
pubmed: 32860705
pmcid: 7953733
doi: 10.1084/jem.20191166
Liu, X. et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 76, 1578–1590 (2016).
pubmed: 26979791
pmcid: 4800826
doi: 10.1158/0008-5472.CAN-15-2524
Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4
pubmed: 35110735
pmcid: 9166916
doi: 10.1038/s41586-021-04390-6
Anderson, N. D. et al. Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia. Nat. Med. 29, 1700–1709 (2023).
pubmed: 37407840
pmcid: 10353931
doi: 10.1038/s41591-023-02415-3
Xia, A. et al. T cell dysfunction in cancer immunity and immunotherapy. Front. Immunol. 10, 1719 (2019).
pubmed: 31379886
pmcid: 6659036
doi: 10.3389/fimmu.2019.01719
Vandenberghe, P. et al. Ligation of the CD5 or CD28 molecules on resting human T cells induces expression of the early activation antigen CD69 by a calcium- and tyrosine kinase-dependent mechanism. Immunology 78, 210–217 (1993).
pubmed: 7682535
pmcid: 1421815
Kunzmann, V. et al. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96, 384–392 (2000).
pubmed: 10887096
doi: 10.1182/blood.V96.2.384.013k07_384_392
Weinkove, R. et al. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin. Transl. Immunol. 8, e1049 (2019).
doi: 10.1002/cti2.1049
Kuball, J. et al. Cooperation of human tumor-reactive CD4
pubmed: 15664164
doi: 10.1016/j.immuni.2004.12.005
Braham, M. V. J. et al. Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model. Oncoimmunology 7, e1434465 (2018).
pubmed: 29872571
pmcid: 5980416
doi: 10.1080/2162402X.2018.1434465
Eagle, R. A., Jafferji, I. & Barrow, A. D. Beyond stressed self: evidence for NKG2D ligand expression on healthy cells. Curr. Immunol. Rev. 5, 22–34 (2009).
pubmed: 19626129
pmcid: 2713595
doi: 10.2174/157339509787314369
Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341–1355 (2019).
pubmed: 31501612
doi: 10.1038/s41591-019-0564-6
Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 380–390 (2016).
pubmed: 26885860
doi: 10.1016/j.immuni.2016.01.021
Philipson, B. I. et al. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling. Sci. Signal. 13, eaay8248 (2020).
pubmed: 32234960
pmcid: 7883633
doi: 10.1126/scisignal.aay8248
Payne, K. K. et al. BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells. Science 369, 942–949 (2020).
pubmed: 32820120
pmcid: 7646930
doi: 10.1126/science.aay2767
Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189–1198 (2022).
pubmed: 35534566
pmcid: 9205778
doi: 10.1038/s41591-022-01800-8
Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934–941 (2022).
pubmed: 35130560
pmcid: 8967714
doi: 10.1038/s41586-022-04489-4
Guerra, N. & Lanier, L. L. Emerging concepts on the NKG2D receptor–ligand axis in health and diseases. Front. Immunol. 11, 562 (2020).
pubmed: 32318064
pmcid: 7155425
doi: 10.3389/fimmu.2020.00562
Gumber, D. & Wang, L. D. Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. EBioMedicine 77, 103941 (2022).
pubmed: 35301179
pmcid: 8927848
doi: 10.1016/j.ebiom.2022.103941
Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878–1887 (2020).
pubmed: 33020644
pmcid: 8446909
doi: 10.1038/s41591-020-1061-7
Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563–571 (2018).
pubmed: 29713085
pmcid: 6117613
doi: 10.1038/s41591-018-0010-1
Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270–274 (2019).
pubmed: 31207604
pmcid: 7698992
doi: 10.1038/s41586-019-1324-y
Philip, M. & Schietinger, A. CD8
pubmed: 34253904
doi: 10.1038/s41577-021-00574-3
Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168, 724–740 (2017).
pubmed: 28187291
pmcid: 5553442
doi: 10.1016/j.cell.2017.01.016
Peng, W. et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res. 72, 5209–5218 (2012).
pubmed: 22915761
pmcid: 3476734
doi: 10.1158/0008-5472.CAN-12-1187
Oh, D. Y. & Fong, L. Cytotoxic CD4
pubmed: 34910940
pmcid: 8809482
doi: 10.1016/j.immuni.2021.11.015
Hashimoto, K. et al. Single-cell transcriptomics reveals expansion of cytotoxic CD4 T cells in supercentenarians. Proc. Natl Acad. Sci. USA 116, 24242–24251 (2019).
pubmed: 31719197
pmcid: 6883788
doi: 10.1073/pnas.1907883116
Li, G. et al. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs. JCI Insight 3, e121322 (2018).
pubmed: 30232281
pmcid: 6237232
doi: 10.1172/jci.insight.121322
Hirabayashi, K. et al. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat. Cancer 2, 904–918 (2021).
pubmed: 34746799
pmcid: 8570569
doi: 10.1038/s43018-021-00244-2
Chen, S. et al. Prognostic and therapeutic significance of BTN3A proteins in tumors. J. Cancer 12, 4505–4512 (2021).
pubmed: 34149914
pmcid: 8210570
doi: 10.7150/jca.57831
Liang, F. et al. Comprehensive analysis of BTN3A1 in cancers: mining of omics data and validation in patient samples and cellular models. FEBS Open Bio. 11, 2586–2599 (2021).
pubmed: 34293829
pmcid: 8409294
doi: 10.1002/2211-5463.13256
Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839–852 (2020).
pubmed: 32888407
doi: 10.1016/S0140-6736(20)31366-0
Azangou-Khyavy, M. et al. CRISPR/Cas: from tumor gene editing to T cell-based immunotherapy of cancer. Front. Immunol. 11, 2062 (2020).
pubmed: 33117331
pmcid: 7553049
doi: 10.3389/fimmu.2020.02062
Textor, A. et al. CD28 co-stimulus achieves superior CAR T cell effector function against solid tumors than 4-1BB co-stimulus. Cancers 13, 1050 (2021).
pubmed: 33801448
pmcid: 7958604
doi: 10.3390/cancers13051050
Pichler, A. C. et al. TCR-independent CD137 (4-1BB) signaling promotes CD8
pubmed: 37392737
pmcid: 10649891
doi: 10.1016/j.immuni.2023.06.007
Driehuis, E., Kretzschmar, K. & Clevers, H. Establishment of patient-derived cancer organoids for drug-screening applications. Nat. Protoc. 15, 3380–3409 (2020).
pubmed: 32929210
doi: 10.1038/s41596-020-0379-4
Driehuis, E. et al. Oral mucosal organoids as a potential platform for personalized cancer therapy. Cancer Discov. 9, 852–871 (2019).
pubmed: 31053628
doi: 10.1158/2159-8290.CD-18-1522
Huch, M. et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell 160, 299–312 (2015).
pubmed: 25533785
pmcid: 4313365
doi: 10.1016/j.cell.2014.11.050
Saltsman, J. A. et al. A human organoid model of aggressive hepatoblastoma for disease modeling and drug testing. Cancers 12, 2668 (2020).
pubmed: 32962010
pmcid: 7563272
doi: 10.3390/cancers12092668
Miao, Y. et al. Next-generation surrogate Wnts support organoid growth and deconvolute Frizzled pleiotropy in vivo. Cell Stem Cell 27, 840–851 (2020).
pubmed: 32818433
pmcid: 7655723
doi: 10.1016/j.stem.2020.07.020
Jutz, S. et al. Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: simultaneous measurement of NF-κB, NFAT and AP-1. J. Immunol. Methods 430, 10–20 (2016).
pubmed: 26780292
doi: 10.1016/j.jim.2016.01.007
Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR–Cas9. Nat. Biotechnol. 34, 184–191 (2016).
pubmed: 26780180
pmcid: 4744125
doi: 10.1038/nbt.3437
Muraro, M. J. et al. A single-cell transcriptome atlas of the human pancreas. Cell Syst. 3, 385–394 (2016).
pubmed: 27693023
pmcid: 5092539
doi: 10.1016/j.cels.2016.09.002
Wu, T. et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).
pubmed: 34557778
pmcid: 8454663